Industry news that matters to you.  Learn more

Archives for December 2013

In-Hospital Heart Failure Therapy Study Offers Compelling Evidence Serial Testing of The Cardiac Biomarker ST2 Can Save Lives

Critical Diagnostics recently announced that results of a University Hospital Basel study of just over 200 acute heart failure patients followed over a three-and-a-half year period, showed that testing of the cardiac biomarker ST2 in-hospital may help to identify a high-risk population with particular benefit from tailored therapy at discharge.

CAMH and Assurex Health Launch Joint Venture to Advance Personalized Medicine in Canada

The Centre for Addiction and Mental Health (CAMH), Canada’s leading hospital for mental health, and Assurex Health, a global leader in personalized medicine, have signed an agreement for a joint venture to bring the benefits of this treatment approach to more Canadians.

Global Genomics Group (G3) to Collaborate with Metabolon on Pan-Omic GLOBAL Study to Discover Cardiovascular Disease Biomarkers and Drug Targets

Global Genomics Group (G3) and Metabolon recently announced that they have entered into a collaboration agreement to investigate biological networks and pathways in order to discover novel biomarkers and pharmaceutical targets for cardiovascular diseases. Under the terms of the agreement, Metabolon will analyze the biochemicals for the GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study. GLOBAL is the largest pan-omic study combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows the precise disease classification in patients.

Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test

Assurex Health, a leading personalized medicine company, recently announced the publication of a third clinical study providing evidence for the effectiveness of the GeneSight combinatorial pharmacogenomic test over the current method for selecting psychotropic medications. The study results were published in the November 2013 issue of Discovery Medicine. Consistent with two previous clinical trials, the Pine Rest study concluded that patients are more than twice as likely to respond when treatment is guided by GeneSight compared to treatment as usual. Importantly, GeneSight also identified 30% of patients with severe gene-drug interactions who had the greatest improvement in depressive symptoms when switched to medications concordant with their genetic profile.

QIAGEN Offers Clinical Labs Early Access to New Ingenuity Solution for Streamlined Interpretation of Patient Sequencing Data

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced it has begun enrolling molecular diagnostics laboratories in an Early Access Program to complete the development of a new web-based solution to deliver faster, easier-to-use and high-confidence clinical interpretation and reporting of observed gene variants in data from next-generation sequencing (NGS)-based tests. QIAGEN announced the program last month at the annual meeting of the Association for Molecular Pathology (AMP) in Phoenix, Arizona.